| MSD Merck Sharp & Dohme AG - Ivemend 150 mg, Pulver zur Herstellung einer Infusionslösung |
| 57913 | | 02 | | Ivemend 150 mg | | Pulver zur Herstellung einer Infusionslösung | | A04AD12 | | Aprepitant | | 14.03.2011 | | |
|
| Composition |
| Praeparatio cryodesiccata: fosaprepitantum 150 mg ut dimeglumini fosaprepitantum, dinatrii edetas, polysorbatum 80, lactosum, natrii hydroxidum ad pH, acidum hydrochloridum ad pH pro vitro corresp. natrium 1.89 mg. |
| Packungsbestandteile |
| Praeparatio cryodesiccata: | | | Lyophilisate | | | | | | | | Active Agent | Dose |
|---|
| Fosaprepitantum | 150 mg |
| | BAG: Active Agent | Dose |
|---|
| Fosaprepitantum | 150 mg |
| | | | Inactive agents |
|---|
| Acidum Hydrochloridum ad Ph | | Dinatrii Edetas | | Lactosum | | Natrii Hydroxidum ad Ph | | Polysorbatum 80 |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 003 | Durchstechflasche(n) | 58.24 | 79.75 | B | SL | No |
|
